Skip to Content


In the US, Verteporfin (verteporfin systemic) is a member of the drug class miscellaneous antineoplastics and is used to treat Macular Degeneration.

US matches:



ATC (Anatomical Therapeutic Chemical Classification)


CAS registry number (Chemical Abstracts Service)


Chemical Formula


Molecular Weight


Therapeutic Categories

Ophthalmic agent

Photosensitizing agent, used in photodynamic therapy (PDT)

Treatment of neovascular (wet) age-related macular degeneration

Chemical Names

23H,25H-Benzo[b]porphine-9,13-dipropanoic acid, 18-etenyl-4,4a-dihydro-3,4-bis(metoxycarbonyl)-4a,8,14,19-tetra- metyl-, monometyl ester, trans- (USAN)

A mixture (50:50) of: (±)-trans-3,4-Dicarboxy-4,4a-dihydro-4a,8,14,19-tetrametyl-18-vinyl-23H,25H-benzo[b]porphine-9,13-dipropionic acid, 3,4,9-trimetyl ester and (±)-trans-3,4-Dicarboxy-4,4a-dihydro-4a,8,14,19-tetrametyl-18-vinyl-23H,25H-benzo[b]porphine (WHO)

Foreign Names

  • Verteporfinum (Latin)
  • Verteporfin (German)
  • Vertéporfine (French)
  • Verteporfina (Spanish)

Generic Names

  • Verteporfin (OS: USAN, BAN, JAN)
  • Vertéporfine (OS: DCF)
  • BPD (IS)
  • BPD-MA (IS)
  • CL 318952 (IS: CDN)
  • FF 18 (IS)
  • Verteporfin (PH: USP 38)

Brand Names

  • Visudyne
    Grupo Novartis, Spain; Novartis, Argentina; Novartis, Belgium; Novartis, China; Novartis, Czech Republic; Novartis, Denmark; Novartis, Ecuador; Novartis, Finland; Novartis, France; Novartis, Hong Kong; Novartis, Croatia (Hrvatska); Novartis, Indonesia; Novartis, Ireland; Novartis, Israel; Novartis, Japan; Novartis, South Korea; Novartis, Lebanon; Novartis, Lithuania; Novartis, Malaysia; Novartis, Netherlands; Novartis, Norway; Novartis, New Zealand; Novartis, Poland; Novartis, Portugal; Novartis, Sweden; Novartis, Slovakia; Novartis, Thailand; Novartis, Turkey; Novartis, Taiwan; Novartis AH, South Africa; Novartis Europharm, Austria; Novartis Europharm, Greece; Novartis Europharm Limited, Latvia; Novartis Farma, Italy; Novartis Healthcare, Philippines; Novartis Ophthalmics, Hungary; Novartis Ophthalmics, Peru; Novartis Ophthalmics, Singapore; Novartis Pharma, Switzerland; Novartis Pharma, Germany; Novartis Pharmaceuticals, Australia; Novartis Pharmaceuticals, Canada; Novartis Pharmaceuticals UK, United Kingdom; Valeant, United States


BANBritish Approved Name
DCFDénomination Commune Française
ISInofficial Synonym
JANJapanese Accepted Name
OSOfficial Synonym
PHPharmacopoeia Name
Rec.INNRecommended International Nonproprietary Name (World Health Organization)
USANUnited States Adopted Name
WHOWorld Health Organization

Further information on drug naming conventions: International Nonproprietary Names.

Important Notice: The international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.